Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T Cell Therapy

04:31 EDT 20 Jun 2017 | Genetic Engineering News

Cell Medica is buying Catapult Therapy TCR and the firm's gene-modified WT1-TCR T cell therapy candidate. The treatment is currently in Phase I/II development for the potential treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Catapult Therapy TCR is a special purpose vehicle established by The Cell and Gene Therapy Catapult (CGT Catapult), UCL Business (UCLB) and Imperial lnnovations, to develop the WT1-TCR T cell therapy, which was originally discovered by researchers at University College London (UCL) and Imperial College London.  Financial details of the acquisition were not disclosed. Cell Medical says it plans to apply its Dominant TCR platform to generate a more effective WT1 TCR product that could also feasibly be used to treat challenging solid tumors, including mesothelioma and ovarian cancer. The firm acquired the Dominant TCR technology from UCLB in 2016. London, U.K.-based Cell Medica and CGT Catapult will carry ...

Original Article: Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T Cell Therapy


More From BioPortfolio on "Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T Cell Therapy"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...